Abasaglar ® (insulin glargin)

För fullständig produktresumé för Abasaglar® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

ABASAGLAR® (insulin glargin): Användning med COVID-19-vacciner

Användningen av vacciner mot SARS-CoV-2 hos patienter som behandlas med Abasaglar har inte studerats.

SE_cFAQ_BIV069_USE_WITH_COVID-19_VACCINES
cFAQ
cFAQ
SE_cFAQ_BIV069_USE_WITH_COVID-19_VACCINES
en-GB

Administration of COVID-19 Vaccines to Patients Receiving Abasaglar

Severe acute respiratory syndrome coronavirus 2 is an emerging virus that has caused the COVID-19 pandemic. Recently, vaccines have been developed against SARS-CoV-2 and some of them are already available.1-4

SARS-CoV-2 Vaccination With Abasaglar

The use of a SARS-CoV-2 vaccine in patients treated with Abasaglar has not been studied by Lilly.

Decisions regarding the use of any vaccination, including SARS-CoV-2 vaccines, in patients treated with Abasaglar should be made at the discretion of the prescribing physician using their best clinical judgment, and must be made by the clinician after careful consideration of risk factors of the patient and the risks and benefits of vaccination.

Possible impact of vaccination on blood glucose concentration

The International Diabetes Federation IDF states that after any vaccination the blood glucose levels might rise for a few days.5

Further resources on COVID-19 Vaccines and Diabetes

For information on COVID-19 vaccines and diabetes, please refer to

For current information on COVID-19 and COVID-19 vaccines in general, please refer to

References

1Dong Y, Dai T, Wei Y, et al. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020;5(1):237. https://doi.org/10.1038/s41392-020-00352-y

2Jackson LA, Anderson EJ, Rouphael NG, et al; mRNA-1273 Study Group. An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med. 2020;383(20):1920-1931. https://doi.org/10.1056/NEJMoa2022483

3COVID-19 vaccines. Centers for Disease Control and Prevention. Updated December 31, 2020. Accessed January 4, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html

4Draft landscape of COVID-19 candidate vaccines. World Health Organization (WHO). November 12, 2020. Accessed December 4, 2020. https://www.who.int/docs/default-source/blue-print/novel-coronavirus-landscape-covid-19-(7).pdf?sfvrsn=a4e55ae3_2&download=true

5International Diabetes Federation Europe. Diabetes & Coronavirus Vaccination. https://idf.org/our-network/regions-members/europe/europe-news/370-diabetes-coronavirus-vaccination.html. Accessed April 29, 2021

6Coronavirus disease (COVID-19) outbreak. European web page of the World Health Organization. Accessed March 20, 2020. http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19

7International Diabetes Federation Europe. COVID-19 outbreak: guidance for people with diabetes. https://www.idf.org/our-network/regions-members/europe/europe-news/196-information-on-corona-virus-disease-2019-covid-19-outbreak-and-guidance-for-people-with-diabetes.html. Accessed March 18, 2020

8COVID-19. European Centre for Disease Prevention and Control. Accessed March 20, 2020. https://www.ecdc.europa.eu/en/novel-coronavirus-china

Glossary

Abasaglar = Abasaglar® (insulin glargine) 100 units/mL

COVID-19 = coronavirus disease 2019

Lilly = Eli Lilly and Company

SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2

Datum fӧr senaste ӧversyn 2021 M01 04


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Klicka för att chatta är tillgänglig

Klicka för att chatta är offline

Skriv din fråga till oss